JPMorgan Chase & Co. Sells 194,513 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

JPMorgan Chase & Co. trimmed its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 70.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 82,691 shares of the specialty pharmaceutical company's stock after selling 194,513 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.26% of Collegium Pharmaceutical worth $2,369,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Principal Financial Group Inc. raised its stake in shares of Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after purchasing an additional 64,958 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Collegium Pharmaceutical by 0.7% during the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company's stock valued at $29,974,000 after purchasing an additional 5,464 shares in the last quarter. Royce & Associates LP raised its stake in shares of Collegium Pharmaceutical by 11.0% during the fourth quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company's stock valued at $9,728,000 after purchasing an additional 33,674 shares in the last quarter. Hillsdale Investment Management Inc. raised its stake in shares of Collegium Pharmaceutical by 1.0% during the fourth quarter. Hillsdale Investment Management Inc. now owns 116,200 shares of the specialty pharmaceutical company's stock valued at $3,329,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Collegium Pharmaceutical by 5.8% during the fourth quarter. Rhumbline Advisers now owns 108,228 shares of the specialty pharmaceutical company's stock valued at $3,101,000 after purchasing an additional 5,920 shares in the last quarter.

Collegium Pharmaceutical Trading Up 2.7 %

Shares of NASDAQ:COLL traded up $0.73 during midday trading on Tuesday, reaching $27.60. The company had a trading volume of 250,977 shares, compared to its average volume of 443,114. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $42.29. The firm has a market cap of $886.84 million, a price-to-earnings ratio of 11.90 and a beta of 0.76. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company has a fifty day simple moving average of $28.30 and a two-hundred day simple moving average of $30.60.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Scott Dreyer sold 2,255 shares of Collegium Pharmaceutical stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the sale, the executive vice president now directly owns 124,421 shares in the company, valued at $3,732,630. The trade was a 1.78 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Colleen Tupper sold 977 shares of Collegium Pharmaceutical stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the sale, the chief financial officer now owns 164,269 shares of the company's stock, valued at approximately $4,928,070. This represents a 0.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 81,693 shares of company stock worth $2,334,994. 2.51% of the stock is currently owned by company insiders.

Analyst Ratings Changes

COLL has been the topic of a number of recent analyst reports. Needham & Company LLC restated a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. Piper Sandler decreased their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research report on Tuesday, February 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $43.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.